The Potential Role of PD-1 x VEGF Bispecific Antibodies in the Management of Non-Small Cell Lung Cancer

Content Validation and Disclosures

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — Fionnuala Crowley, MD, has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities: Sid Devarakonda, MD — Consulting Agreements: Apollomics Inc; Scientific/Medical Advisory Boards: Acrotech Biopharma, Amgen Inc, Apollomics Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, IDEAYA Biosciences, Johnson & Johnson, Lilly, Natera Inc, Nuvation Bio Inc; Research Grant Site Principal Investigator: AstraZeneca Pharmaceuticals LP; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Johnson & Johnson. Neal E Ready, MD, PhD — Scientific/Medical Advisory Boards: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, G1 Therapeutics Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Regeneron Pharmaceuticals Inc. Additional faculty to be announced.